PeptideFactSheetsAn independent reference
Menu

Lipid-linked cosmetic peptide · Fact sheet

Palmitoyl pentapeptide-4

Also known as Pal-KTTKS · Palmitoyl-Lys-Thr-Thr-Lys-Ser

Palmitoyl pentapeptide-4 is a lipid-linked peptide studied in topical skin products. Small formulation-specific trials report wrinkle changes; those findings do not establish systemic anti-aging, wound treatment or injectable use.

Not FDA approvedEarly human evidence
Skin & hair

What is Palmitoyl pentapeptide-4?

Pal-KTTKS contains a five-amino-acid sequence linked to a palmitoyl group.

The Matrixyl trade-name family includes different ingredients and mixtures, so the trade name alone does not identify this exact peptide.

Benefits & claims

Interest centers on skin or hair appearance. Biological activity does not itself establish a clinical treatment.

What the evidence supports

  • The split-face study reported improved wrinkle/fine-line appearance with the peptide-containing moisturizer.
  • The smaller trial was preliminary and formulation-specific.
  • Appearance measures do not demonstrate reversal of biological aging or benefit from a different route.
Research areas
  • Experimental tissue and cellular responses
  • Formulation-specific outcomes

Dosage & frequency

No established human regimen

Topical human studies report formulation-specific appearance outcomes, not an established therapeutic amount or frequency for this peptide.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Studied topical formulation
The 93-person split-face study used a moisturizer containing 3 ppm pal-KTTKS for 12 weeks. Concentration does not specify the absolute applied dose; the indexed report does not verify a universal application frequency.
Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin.

Formulation differences

  • The Matrixyl trade-name family includes different ingredients and mixtures, so the trade name alone does not identify this exact peptide.

Interactions & precautions

  • The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.

What is still unresolved

  • Controlled human clinical outcomes for the exact substance
  • Human exposure, pharmacokinetics and repeated-use safety
  • Independent replication and formulation equivalence
Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. FDA: cosmetics and U.S. law

Side effects & risks

  • Topical irritation, allergy and long-term formulation-specific tolerability need evaluation.
  • Cosmetic-product safety is not equivalent to systemic peptide safety.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

A 93-woman split-face study compared a moisturizer with and without 3 ppm pal-KTTKS over 12 weeks. A separate 21-person study compared several creams.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

No attributable personal accounts were found in the sources reviewed.

Approval status

Palmitoyl pentapeptide-4 has no FDA-approved therapeutic product. The cited experiments or cosmetic uses do not establish an approved human treatment.

No FDA-approved product for this entry

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Controlled human clinical outcomes for the exact substance
  • Human exposure, pharmacokinetics and repeated-use safety
  • Independent replication and formulation equivalence

Summary

Appearance measures do not demonstrate reversal of biological aging or benefit from a different route.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  3. fdaFDA: cosmetics and U.S. law

    Cosmetic ingredients generally do not receive FDA premarket approval; disease and structure/function claims can invoke drug regulation.

How we assess sources · Suggest a correction